{
  "success": true,
  "pagesUsed": [
    3,
    9,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    23,
    34,
    57
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "scheduling": {
    "timings": [
      {
        "id": "timing_1",
        "name": "Screening Window",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": 28,
        "windowLower": -28,
        "windowUpper": -2
      },
      {
        "id": "timing_2",
        "name": "Washout Period",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": [
          3,
          14
        ],
        "relativeTo": "Previous Visit",
        "windowLower": 3,
        "windowUpper": 14
      },
      {
        "id": "timing_3",
        "name": "Follow-up Visit Window",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 28,
        "relativeTo": "Last Dose",
        "windowLower": -2,
        "windowUpper": 2
      },
      {
        "id": "timing_4",
        "name": "CRU Discharge",
        "type": "After",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 6,
        "relativeTo": "Last Dose"
      },
      {
        "id": "timing_5",
        "name": "Study Drug Administration after Hypoglycemia",
        "type": "After",
        "unit": "minutes",
        "instanceType": "Timing",
        "value": 5
      },
      {
        "id": "timing_6",
        "name": "PK/PD Sampling Duration",
        "type": "Within",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "Last Dose",
        "windowLower": 0,
        "windowUpper": 4
      },
      {
        "id": "timing_7",
        "name": "Immunogenicity Follow-up Sampling",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 84,
        "relativeTo": "Previous Visit",
        "windowLower": -7,
        "windowUpper": 7
      }
    ],
    "conditions": [
      {
        "id": "cond_1",
        "name": "CRU Admission Rescheduling",
        "instanceType": "Condition",
        "description": "Condition for rescheduling admission to the CRU on Day 1.",
        "text": "Admission can be rescheduled if Plasma Glucose (PG) level is not 90 to 250 mg/dL on Day 1."
      },
      {
        "id": "cond_2",
        "name": "Stop Insulin Infusion",
        "instanceType": "Condition",
        "description": "Condition to stop the insulin infusion used to induce hypoglycemia.",
        "text": "Insulin infusion is stopped once bedside Plasma Glucose (PG) is <60 mg/dL."
      },
      {
        "id": "cond_3",
        "name": "Interim Safety Review",
        "instanceType": "Condition",
        "description": "A safety review is required after a subset of patients complete Period 2 before dosing the remaining patients.",
        "text": "Safety data will be reviewed after the first 6 patients are administered LY900018 in Period 2. The remaining patients will be dosed after confirmation of the safety."
      },
      {
        "id": "cond_4",
        "name": "Study Stopping Rule",
        "instanceType": "Condition",
        "description": "The entire study may be stopped based on the interim safety review.",
        "text": "Following the review of the safety data from the first 6 patients to complete Period 2 Day 1, the study will be stopped if deemed necessary for patient safety in the opinion of the Investigator and sponsor."
      },
      {
        "id": "cond_5",
        "name": "Additional Follow-up for TE ADA",
        "instanceType": "Condition",
        "description": "Condition triggering an extended follow-up period for immunogenicity testing.",
        "text": "Patients with treatment-emergent antidrug antibodies (TE ADA) at follow-up/ED will undergo additional follow-up."
      },
      {
        "id": "cond_6",
        "name": "Patient Replacement Criteria",
        "instanceType": "Condition",
        "description": "Criteria for replacing a discontinued patient.",
        "text": "If patients discontinue from the study before completion of both periods with evaluable primary outcome for any reason, the patient may be replaced. Replacement should not occur beyond 75 patients enrolled."
      },
      {
        "id": "cond_7",
        "name": "Inadvertent Enrollment",
        "instanceType": "Condition",
        "description": "Condition where a patient is found to not meet enrollment criteria after being enrolled.",
        "text": "The sponsor or investigator identifies a patient who did not meet enrollment criteria and was inadvertently enrolled."
      }
    ],
    "conditionAssignments": [],
    "transitionRules": [
      {
        "id": "trans_1",
        "name": "Screening to Treatment Period 1",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "Screening",
        "toElementId": "Period 1",
        "text": "Patients who complete screening and meet all eligibility criteria will be randomized and proceed to Treatment Period 1."
      },
      {
        "id": "trans_2",
        "name": "Period 1 to Period 2",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "Period 1",
        "toElementId": "Period 2",
        "text": "After completing Period 1, patients enter a washout period of 3 to 14 days before starting Period 2."
      },
      {
        "id": "trans_3",
        "name": "Discontinuation of Inadvertently Enrolled Patients",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "If an inadvertently enrolled patient is identified, a discussion must occur between the Lilly CP/CRP and the investigator to determine if the patient may continue. If both agree it is medically appropriate, documented approval must be obtained to allow the patient to continue."
      }
    ],
    "scheduleTimelineExits": [
      {
        "id": "exit_1",
        "name": "Patient Decision",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "The patient, or legal representative, requests to be withdrawn from the study."
      },
      {
        "id": "exit_2",
        "name": "Investigator Decision",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "The investigator decides that the patient should be discontinued from the study for any reason. If due to an AE/SAE, appropriate measures are to be taken."
      },
      {
        "id": "exit_3",
        "name": "Other Study Enrollment",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Enrollment in any other clinical study involving an investigational product or other incompatible medical research."
      },
      {
        "id": "exit_4",
        "name": "Medical, Safety, or Regulatory Reasons",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Participation in the study needs to be stopped for medical, safety, regulatory, or other reasons consistent with applicable laws, regulations, and good clinical practice."
      },
      {
        "id": "exit_5",
        "name": "Lost to Follow-up",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A patient is considered lost to follow-up if they repeatedly fail to return for scheduled visits and cannot be contacted by the study site."
      },
      {
        "id": "exit_6",
        "name": "Study Completion",
        "exitType": "Completion",
        "instanceType": "ScheduleTimelineExit",
        "description": "Patient completes both treatment periods and the final follow-up visit."
      }
    ],
    "scheduledDecisionInstances": [
      {
        "id": "dec_1",
        "name": "Interim Safety Review Decision",
        "timepointId": "After first 6 patients complete Period 2",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point to continue dosing remaining patients or stop the entire study based on a safety review of the first 6 patients to complete Period 2.",
        "conditionIds": [
          "cond_3",
          "cond_4"
        ]
      },
      {
        "id": "dec_2",
        "name": "Inadvertent Enrollment Decision",
        "timepointId": "Post-enrollment",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point to determine if an inadvertently enrolled patient should continue in the study or be discontinued.",
        "conditionIds": [
          "cond_7"
        ]
      },
      {
        "id": "dec_3",
        "name": "Additional Follow-up Decision",
        "timepointId": "Follow-up Visit",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision to initiate an extended immunogenicity follow-up schedule for patients who are positive for treatment-emergent antidrug antibodies.",
        "conditionIds": [
          "cond_5"
        ]
      }
    ],
    "summary": {
      "timingCount": 7,
      "conditionCount": 7,
      "transitionRuleCount": 3,
      "exitCount": 6
    }
  }
}